Peptide–Major Histocompatibility Complex class I complexes presenting Survivin, PRAME, MAGE-A4, SSX2, and NY-ESO-1 tumor-associated antigen peptides (pMHC-I (Survivin/PRAME/MAGE-A4/SSX2/NY-ESO-1))

Other names

MultiTAA-pMHC complexesTumor-associated antigen peptide-MHC complexesTAA-pMHC complexesSurvivin/PRAME/MAGE-A4/SSX2/NY-ESO-1 pMHCmTAA-pMHC

The target consists of specific peptide fragments from tumor-associated antigens (TAAs) bound to MHC class I molecules on the surface of cancer cells. These complexes are recognized by the T-cell receptors (TCRs) of cytotoxic T lymphocytes (CTLs). Therapeutic intervention involves the administration of ex vivo expanded T cells (multiTAA-T) or engineered TCR-T cells that bind to these pMHC complexes, leading to T-cell activation, secretion of inflammatory cytokines (e.g., IFN-gamma), and direct lysis of the tumor cells [3, 4, 10].